ANI launches generic Motegrity
ANI is offering prucalopride tablets, which is the generic of Takeda's Motegrity.
Motegrity is used in adults to treat chronic idiopathic constipation.
"We are delighted to build momentum early in 2025 with the approval of the first generic for Motegrity, once again highlighting our superior R&D capabilities. The FDA has granted our Prucalopride Tablets a Competitive Generic Therapy (CGT) designation, with 180-day exclusivity. ANI continues to hold the second-highest number of CGT approvals in the U.S. Generics market,” said Nikhil Lalwani, president and CEO of ANI.
[Read more: ANI intros generic Trental]
Prucalopride Tablets had a market value of approximately $168 million, per IQVIA October 2024 data.
[Read more: ANI Pharmaceuticals receives FDA nod for generic Furadantin]